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Lymphangioleiomyomatosis (LAM) is a rare lung disease which predominantly affects young
women. LAM is associated with much morbidity and can lead to respiratory failure and death
unless lung transplantation is performed. There are no randomised trials of treatment and no
consensus on the management of LAM. In order to produce guidelines for a rare disease where
little evidence exists we have adapted existing guideline methodology to evaluate what
evidence and knowledge there is to produce a consensus based statement. The process of
guideline development comprised forming a group of experts in LAM and related fields
including pathology, radiology, tuberous sclerosis and transplantation. Questions were formu-
lated and the available evidence formed into a series of recommendations. Consensus agree-
ment amongst the group was reached by a series of reviews with scoring of agreement, and
proposals for modifications, using Likert statistics. The recommendation strength was graded
using the American College of Chest Physicians health and science policy grading system
according to the quality of evidence, magnitude of benefit, strength of recommendation
and strength of consensus achieved. The guidelines describe the diagnostic criteria for LAM
and recommended investigations and criteria for the diagnosis and appropriate work up for
the diagnosis of LAM. All aspects of management from advice for patients to lung transplanta-
tion are discussed. To demonstrate how the guidelines have dealt with different areas of
practice and differing evidence levels the specific areas of hormonal therapy, pneumothorax
and lung transplantation for LAM are discussed. It is hoped that these guidelines will result
in standardisation of diagnostic criteria and patient management which will further improve
clinical care and facilitate research and clinical trials.
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S34 S.R. JohnsonLymphangioleiomyomatosis (LAM) is an orphan pulmonary
which almost exclusively affects women. The disease is rare
with a prevalence of about 2 per million of the population.
LAM may occur in isolation (sporadic-LAM) or in association
with the genetic disease tuberous sclerosis (TSCeLAM). The
main manifestations are pulmonary with patients devel-
oping progressive cystic change in the lungs leading to
dyspnoea, recurrent pneumothorax and less frequently
chylous collections in the thorax.1 Extra pulmonary mani-
festations of LAM include enlargement and occlusion of the
axial lymphatics of the abdomen and pelvis occasionally
forming cystic structures called lymphangioleiomyomas,
lymphadenopathy and occasional chylous ascites. Approxi-
mately 40% of women with LAM also have angiomyolipoma,
a benign tumour which generally occurs in the kidneys but
occasionally other sites.2 At a pathological level LAM is
characterised by the infiltration of involved tissues with an
abnormal type of smooth muscle related cell termed the
LAM cell. These have a characteristic mixed phenotype
expressing smooth muscle proteins but also melanoma
related antigens including GP100 and MART1.3 The normal
precursor to these cells is unknown however; although
thought to be benign, LAM cells are clonal and can metas-
tasize throughout the body.4 LAM cells from patients with
either sporadic or TSCeLAM have bi-allelic inactivation of
one of the TSC genes; TSC-1 or more commonly TSC-2.5 This
results in constitutive activation of the mTOR pathway,
uncontrolled cellular proliferation and abnormalities in cell
migration.6
Guideline documents are an increasing part of medical
management. Whilst occasionally seeming prescriptive,
guideline statements are at their most useful when used to
reinforce evidence based practice or to guide those working
outside of their expertise. In the case of rare pulmonary
diseases, including LAM, most patients are at least initially
seen by physicians working outside their area of expertise.
In the UK there are possibly 150 patients with LAM distrib-
uted throughout the country meaning that most respiratory
physicians will at most see one or two patients with the
illness and are therefore unable to build up specificFigure 1 Structure of LAM Task Forceexpertise in the management of these complex patients.
Guidelines in this case will avoid unnecessary investigation,
reduce inappropriate treatments and hopefully improve
management and patient satisfaction. In addition, stand-
ardising management will improve data collection and
eventually facilitate research into the disease.
In order to produce the LAM guidelines two Chairs,
Professor J-F Cordier and myself, were elected at the Euro-
LAM Meeting held in Nottingham in 2005. We then recruited
a core panel of physicians who are independent experts in
LAM from various European countries. In addition,
a consultant panel with specific areas of expertise neces-
sary to make a comprehensive document including
pathology, imaging, TSC and pulmonary transplantation.
The final group of the Task force was the Review Panel
which comprised approximately 30 independent experts
drawn from members of all European National Respiratory
Societies, other international experts and representatives
of patient groups. This panel reviewed all documentation
produced by the Task force. The structure of the Task force
and members of individual panels are shown in Fig. 1. The
Chairs then established the areas to be addressed and after
input from the core panel, questions were allocated to
members of the core and consultant panels according to
their expertise who performed the appropriate searches
from Medline, PubMed and their own files. The evidence
was then tabulated and a review and statement on the
question posed was constructed. Evidence was weighed
according to its quality and graded using the American
College of Chest Physicians health and science policy
grading system7: the net benefit of the intervention and
these factors synthesised to give an overall strength of the
recommendation ranging from (A) strong recommendation
to (D) negative recommendation based on evidence or (EA)
a strong recommendation based on expert opinion only to
(ED) a negative recommendation based on expert opinion
only. For each point scores for the quality of evidence,
benefit and strength of recommendation were given by the
task force and a further score of the level of consensus was
then constructed during the review process.including members of each panel.
Figure 2 Levels of evidence in guideline statements from the
BTS/SIGN Asthma Guidelines, BTS Diffuse Parenchymal Lung
Disease (DPLD) and ERS LAM guidelines. Grades A to D reflect
levels of evidence as described. N Z number of recommen-
dations in each guideline.
Table 1 Likert scoring procedure. Likert response scores (left column) and calculation of consensus (right column).
Response Consensus level
9 Extremely appropriate: treatment of choice Perfect
All respondents agree on an answer
7-8 Appropriate: first-line treatment you would
often use.
Very good
Interquartile range at 1 integer of the median or 80%
within 1 integer of median
4-6 Equivocal: second-line treatment you would
sometimes use
Good
50% within 1 integer of the median or 80% within 2
integers of the median
2-3 Usually inappropriate: at most, third-line
treatment you would rarely use.
Some
50% within 2 integers of the median or 80% within 3
integers of the median
1 Extremely inappropriate: treatment you
would never use
No
All other responses.
ERS LAM guideline methodology S35Dealing with rare diseases poses unique problems for
clinicians and researchers. In the case of LAM, no evidence
has been obtained from randomised control trials (although
at the time of writing two placebo controlled studies looking
at change in lung function in LAM are in progress) and there
is an absence of high quality evidence. Despite this there
remains a need to guide clinicians looking after these
patients and to address this issue we used the Task Force
structure to produce consensus guidelines by the Delphi
method. In this method, the formulated statements based
on the best evidence and opinions of the core and consul-
tant panels were scored by independent experts “the
review panel” using a 9 point Likert Scale (Table 1). For each
point in the guidelines each member of the panel produced
a score and these were then synthesised to a consensus level
according to a pre-arranged method (Table 1). Points with
poor consensus based on Likert scores were re-evaluated
and moderated by the core panel in response to comments
from individual panel members. Reformulated questions
were then subjected to further review by this method and
by a process of iterations the best consensus was produced
for individual points. The Delphi method has the advantage
of being anonymous, giving controlled feedback and can be
analysed statistically.8 After this process a very good or good
level of consensus (as defined above) was reached for all
points but one.
It can be similarly challenging to produce guidelines with
strong levels of evidence for all aspects of the management
of common diseases as well as rare diseases. For example
the strength of evidence for asthma, perhaps the most
common respiratory disease achieves more than 50% of its
recommendations of grade A and B evidence9 but the
British guidelines for diffuse parenchymal lung disease have
almost exclusively grade C and grade D levels of evidence.10
Although the methodology is not completely comparable,
the European LAM guidelines similar strengths of evidence
to diffuse parenchymal lung disease although a small
amount of grade A evidence based upon evidence from
other diseases such as screening for TSC (Fig. 2).
The European LAM Guidelines attempt to produce
a comprehensive, but importantly, practical document to
assist in the management of patients with LAM. The format
of the document comprises an introduction, methodology,
the guidelines proper include recommendations for thediagnosis and work up for patients with LAM including
the first diagnostic criteria to be formally described for the
disease, screening strategies for groups at risk of LAM,
understanding factors predictive of the prognosis. Finally
the section on management considers general advice and
interventions for patients from vaccination, pulmonary
rehabilitation and advice concerning issues of importance
in LAM including the effect of pregnancy upon the disease
course, action to be taken in event of pneumothorax
symptoms, avoidance of oestrogen containing treatments.
Drug treatment, both symptomatic including bronchodila-
tors, oxygen and specific treatments for LAM including
hormone therapy and newer experimental therapies
including the mTOR inhibitors and the metalloproteinase
inhibitor and antibiotic doxycycline. The role of surgical
interventions for pleural complications is discussed. There
is a comprehensive section on the management of angio-
myolipoma. Although specialist management of angiomyo-
lipoma traditionally undertaken by urologists and
S36 S.R. Johnsoninterventional nephrologists or radiologists the Task Force
felt it was important to include this section in the guide-
lines as approximately 40% of these patients will have an
angiomyolipoma and most patients will receive the
majority of their care from their pulmonologist in many
countries. Thus the role of the initial screening for angio-
myolipoma and occasionally emergency presentation due to
bleeding may be the work of pulmonologists. Recommen-
dations for the work up of these patients and referral for
lung transplantation is also considered. The recommenda-
tions are summarised in Table 2.
I will discuss some of the issues from the guidelines in
more detail. For the first-time diagnostic criteria for LAM
have been constructed using criteria based on the larger
published series and expert opinion.11e13 The Task Force
have recommended that a definite diagnosis of LAM can be
made in the presence of a characteristic or compatible high
resolution CT scan and a lung biopsy fitting the pathological
criteria for LAM: or characteristic high resolution CT scan
and any of either angiomyolipoma of the kidney, thoracic or
abdominal chylous effusion, lymphangioleiomyoma or
lymph-node involved by LAM or diagnosis of TSC. In patients
where the CT characteristic but none of the supportive
features are present then a diagnosis of probable LAM is
made. A diagnosis of possible LAM occurs when there is only
CT evidence of a cystic lung disease and no other features.
After iterations through the Delphi process all 30 reviewers
scored this recommendation as seven or greater producing
a consensus level of “very good”. Recommendations for the
pathological diagnosis of LAM were made. In this case three
recommendations were formed the first stating that path-
ological samples from patients with suspected LAM (or
indeed any diffuse parenchymal lung disease) should be
examined by a pathologist experienced in LAM. Recom-
mendation two defines the appearance of LAM in biopsies
stating LAM should be considered when there is a variable
predominance of cysts, multifocal, nodular, proliferating,
smooth muscle cells and perivascular epithelioid cells. The
third recommendation states that immunohistochemistry
for alpha-smooth muscle and HMB45 should be performed
especially where morphologic features do not allow
a secure diagnosis to be made. Oestrogen and progesterone
receptor may be an adjunct to diagnosis. Again a very good
consensus level was reached for the pathologic criteria for
diagnosis with the grade of evidence being grade ‘A expert
opinion’. The quality of the evidence ‘C expert opinion’ and
the benefit being ‘substantial’.
Some of the Task Force recommendations touched upon
areas of controversy particularly with regard to screening
and drug treatment. The question ‘should women with TSC
undergo screening for LAM by high resolution CT scan’ was
addressed. Between 30 and 40% of adult women with TSC
have evidence of cystic lung disease when screened by
CT14,15 however only a small percentage of these women
have symptoms. Despite this, the Task Force felt that there
were benefits from screening as although no definitive
treatment exists: patients may be warned about the
symptoms of pneumothorax, may receive further pregnancy
counselling against the possible adverse effect of preg-
nancy on LAM and can be counselled to avoid oestrogen
supplementation such as the oral contraceptive pill or
hormone replacement therapy which may accelerate thedisease. In its recommendations the Task Force agreed with
the American Tuberous Sclerosis Alliance guidelines that
women with TSC should undergo screening for LAM by high
resolution CT scan of the thorax at the age of 18 years and
then added over and above the American Guidelines that if
negative again at the age of 30e40 years e Quality ‘C’,
benefit ‘L’, strength ‘I’, consensus ‘very good’. The Task
Force also recommended that high resolution CT if negative
should be repeated if persistent respiratory symptoms
develop. The level of consensus on this point was somewhat
lower with some physicians advocating regular screening of
patients with TSC by high resolution CT scan. The third
recommendation complimented the other two stating that
women with TSC should undergo high resolution CT of the
thorax in the presence of otherwise unexplained respira-
tory symptoms: a recommendation applying to existing
patients who have not been screened at the age of 18.
Progesterone is the most commonly used treatment for
women with LAM. Although no good evidence exists of its
efficacy and the only studies to address the issue have been
retrospective case series; one showing a possible short lived
benefit in reduction and decline in lung function the other
being negative.12,16 The Task Force therefore concluded
that: 1) Oral or intramuscular progesterone should not be
used routinely in patients with LAM e grade ‘I’, quality ‘L’,
benefit ‘C’, consensus ‘very good’. 2) That in patients with
rapid decline in lung function or symptoms intramuscular
progesterone may be trialled e grade ‘C’, quality ‘L’,
benefit ‘W’, consensus ‘very good’ and 3) If used, proges-
terone may be given for 3 months with clinical evaluation
and lung function at 3 monthly intervals, if lung function
and symptoms continue to decline at the same rate on
progesterone treatment; after 1 year progesterone should
be withdrawn e grade ‘E/C’, quality ‘E/C’, benefit ‘W’,
consensus ‘very good’. In the latter two recommendations
although overall the consensus was very good a larger
number of physicians disagreed with these recommenda-
tions feeling progesterone should not be prescribed under
any circumstances due to the lack of evidence of efficacy.
The gold standard for management of these patients would
be enrolment in a clinical trial however, in writing the
European LAM Guidelines these will be applied in many
countries across Europe where clinical trials of newer drugs
for LAM are not available and hormone treatment may be
the only option for some patients. This is a difficult situa-
tion as no evidence of efficacy does not mean that there is
absolutely no efficacy as the appropriate studies have not
been performed. Several iterations through the Delphi
process were made to produce a balanced and helpful
guideline to deal with this issue.
The recent finding of deregulation of the mTOR pathway
in LAM and TSC has led to the first clinical trials of biologic
therapy for the disease.17,18 The use of mTOR inhibitors
including Sirolimus shows promise for angiomyolipoma and
possible benefit on lung function in some patients. However
randomised placebo controlled trials for this indication
have not reported and at the current time the Task Force
has recommended that Sirolimus should not be prescribed
routinely outside clinical trials for pulmonary LAM. Patients
with LAM should be encouraged to participate in clinical
trials wherever possible e grade ‘C’, quality ‘L’, benefit
‘W’, consensus ‘very good’. Similarly in renal
Table 2 ERS LAM guidelines.
Diagnosis and investigations
Diagnostic Criteria
Definite LAM
1. Characteristic or compatible lung HRCT and lung biopsy fitting the pathological criteria for LAM
OR
2. Characteristic lung HRCT and any of the following:
- angiomyolipoma (kidney)
- thoracic or abdominal chylous effusion
- lymphangioleiomyoma or lymph-node involved by LAM
- definite or probable TSC
Probable LAM
1. Characteristic HRCT and compatible clinical history
OR
2. Compatible HRCT and any of the following:
- angiomyolipoma (kidney)
- thoracic or abdominal chylous effusion
Possible LAM
Characteristic or compatible HRCT
Pathologic criteria for diagnosis
1. Pathological samples from patients with suspected LAM (or any diffuse parenchymal lung disease) should be examined
by a pathologist experienced in LAM.
2. LAM should be considered when there is a variable predominance of cysts, multifocal, nodular proliferating immature
smooth muscle and perivascular epithelioid cells.
3. Immunohistochemistry for a-smooth muscle actin and HMB45 should be performed especially where morphologic features
do not allow a secure diagnosis to be made. Oestrogen and progesterone receptor may be an adjunct to diagnosis.
Radiologic criteria for diagnosis
1. Patients with suspected LAM should have a pulmonary HRCT scan using a thin collimation, high spatial reconstruction
algorithm.
2. The acquisition may be performed with sequential scanning (images with 1 mm collimation at 1-cm intervals) or low
dose spiral MDCT.
Radiology in abdominal LAM
1. All patients with LAM or suspected LAM should have an abdomino-pelvic CT at diagnosis or during work up to identify
angiomyolipoma and other abdominal lesions.
2. The abdomen should be scanned contiguously with 3 mm collimation or less, before and after the intravenous
administration of non-ionic contrast.
3. Since a proven therapeutic intervention is not currently available for lymphangioleiomyomas, screening of asymptomatic
patients for lymphangioleiomyomas during the course of the disease should not be performed.
4. Patients with abdominal symptoms should be evaluated for the presence of lymphadenopathy or lymphangioleiomyomas
by CT scanning.
Screening for meningioma in patients with sporadic-LAM
1. Brain MRI as a baseline evaluation may be useful for comparison during follow up and should be performed in the
presence of symptoms compatible with meningioma.
2. Brain MRI screening for meningioma should be performed in women with LAM receiving progestative drugs or planned
to receive such treatment.
Work up for TSC in patients with LAM
1. Patients presenting with LAM should have a thorough history and family history taken concerning the manifestations
of TSC. Physical examination should include the skin, retina and nervous systems by a physician familiar with the
manifestations of TSC.
2. Patients with LAM and bilateral angiomyolipoma, and other patients where doubt remains, should be referred to
a clinical geneticist for full evaluation.
3. Routine genetic analysis of patients with sporadic-LAM is not of benefit and should not be performed.
Lung function testing
1. Spirometry, bronchodilator testing, and TLCO should be performed in the initial evaluation of patients with LAM
(including TSCeLAM).
2. FEV1 and TLCO should be performed to assess disease progression and response to treatment.
3. Lung function tests should be repeated every 3e6 months in patients with progressive disease and every 6e12 months
in those with more stable disease, as determined by a period of observation of one year.
(continued on next page)
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Arterial blood gas measurement
1. Blood gases may be performed at initial evaluation of patients with LAM to obtain a baseline value, and in the
assessment of patients with severe disease including before transplant referral.
2. Blood gases should be performed to assess the indication for oxygen therapy in patients with advanced disease.
Cardiopulmonary exercise testing and 6 min walk test (6MWT)
1. Cardiopulmonary exercise testing may be performed to provide additional information over standard lung function
tests in symptomatic patients.
2. The 6MWT may be performed in the evaluation of disability, disease progression, and response to treatment in
symptomatic patients
Screening for pulmonary hypertension
1. Screening for pulmonary hypertension is not recommended in patients with non-severe LAM.
2. Estimation of pulmonary artery pressure by echocardiography may be performed in patients with severe disease
and those requiring long-term oxygen therapy. It should be performed in those considered for lung transplantation.
Screening for LAM in at risk groups
Is CT indicated in women with apparently spontaneous pneumothorax?
1. Chest CT for patients with a first-time pneumothorax should not be performed routinely.
2. Chest CT may be indicated to evaluate the presence of LAM that is suspected clinically but is not apparent on standard
radiographs.
3. The panel did not achieve consensus regarding the utility of chest CT scans for evaluating patients with recurrent
pneumothoraces, persistent air leaks, or planned surgical interventions.
Should women with TSC undergo screening for LAM by high resolution CT scan?
1. Women with TSC should undergo screening for LAM by HRCT of the thorax at the age of 18 and if negative again at
the age of 30e40 years.
2. HRCT should be repeated if persistent respiratory symptoms develop.
3. Women with TSC should undergo HRCT of the thorax in the presence of otherwise unexplained respiratory symptoms.
Should men with TSC be screened for LAM by HRCT?
1. Men with TSC and otherwise unexplained respiratory symptoms should be investigated as dictated by their symptoms;
this may include HRCT scanning.
2. Men without respiratory symptoms should not be screened for LAM with HRCT
Is screening for LAM needed in women with sporadic angiomyolipoma?
1. In patients with unilateral angiomyolipoma, no clinical features of TSC and no pulmonary symptoms, screening for LAM
by HRCT may be performed.
2. In patients with bilateral angiomyolipoma screening for TSC should be performed, with further LAM screening if TSC
is present.
Prognosis
Estimation of prognosis
1. Lung biopsy does not provide prognostic information and should not be performed for this purpose alone.
2. Disease progression may be evaluated by repeating lung function tests at 3e6 monthly intervals during the first year
following diagnosis then at 3-12 monthly intervals depending on the severity and progression of the disease.
Follow up of patients with TSCeLAM with no pulmonary symptoms
1. Regular follow up by a respiratory specialist or serial lung function studies may not be required for patients with
TSCeLAM with normal lung function after initial evaluation and who have been stable after a period of observation of
one year. Follow up respiratory evaluation and lung function should be performed if respiratory symptoms develop.
2. Other health professionals involved in the care of patients with TSC and patients themselves should be informed that
patients experiencing respiratory symptoms should be seen by a respiratory specialist. This may be in an information
document given to patients and general physicians.
Management
Advice for patients on pneumothorax
1. Patients with both sporadic and TSCeLAM including those with no or minimal symptoms must be warned of the risk of
pneumothorax and told to seek urgent medical attention in the event of symptoms of pneumothorax.
Advice for patients and management of pregnancy
1. To become pregnant is the patients’ decision. However all patients, including those with few or no symptoms, should be
informed that there is a greater risk of pneumothorax and chylous effusion during pregnancy. Those with recurrent
pneumothorax or effusion outside pregnancy and those with poor baseline lung function are at greater risk during
pregnancy.
2. Women with LAM who are pregnant should receive information, ideally pre-pregnancy or as soon after conception as
feasible to warn of the risk of pneumothorax, effusion and bleeding from angiomyolipoma.
3. Patients with tuberous sclerosis should further receive genetic counselling prior to conception.
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Table 2 (continued )
4. Patients should be monitored during pregnancy by both a pulmonary physician and an obstetrician informed about LAM.
5. It may be appropriate to discourage patients with severe disease from becoming pregnant, this counsel being given
on an individual basis
Avoidance of oestrogen including the contraceptive pill and hormone replacement
1. Women with LAM should avoid oestrogen containing treatments including the combined oral contraceptive pill and
hormone replacement therapy.
Information for patients concerning air travel
1. Patients with sporadic or TSCeLAM and minimal symptoms should not be discouraged from air travel. They should be
warned that they should not travel if new respiratory symptoms have not been evaluated.
2. Patients with advanced disease should be evaluated for the need for oxygen during flight and should not travel if new
respiratory symptoms have not been evaluated. Those for whom an untreated pneumothorax may have serious
consequences should consider alternatives to air travel.
3. Patients with a known untreated pneumothorax, or a pneumothorax treated within the previous month, should not
travel by air
Pulmonary rehabilitation
1. Pulmonary rehabilitation may be offered to patients with LAM who are limited by dyspnoea.
Influenza and pneumococcal vaccination
1. Influenza and pneumococcal vaccination should be offered to patients with LAM.
Assessment and management of osteoporosis
1. Patients with LAM, especially those post-menopause, should undergo periodic evaluation of bone mineral density.
2. Those with osteoporosis should be treated as other patients with osteoporosis.
3. In view of the rapid deterioration in bone mineral density observed after lung transplantation, aggressive therapy for
osteoporosis should be initiated early in LAM patients with severe lung disease and osteopenia at any bone site. In
addition to pharmacologic therapy, weight-bearing exercise and strength training should be encouraged because of the
growing evidence that exercise improves bone density.
Drug therapy
Inhaled bronchodilators
1. Inhaled bronchodilators should be trialled in patients with airflow obstruction and continued if a response is observed.
Hormone therapy: Progesterone
1. Oral or intramuscular progesterone should not be used routinely in patients with LAM.
2. In patients with rapid decline in lung function or symptoms, intramuscular progesterone may be trialled.
3. If used, progesterone may be given for 12 months with clinical evaluation and lung function at 3 monthly intervals. If
lung function and symptoms continue to decline at the same rate on progesterone treatment after one year,
progesterone should be withdrawn.
Hormone therapy - other anti-oestrogen interventions
1. Hormone treatments other than progesterone should not be used in patients with LAM.
mTOR inhibitors
1. Sirolimus should not be prescribed routinely outside clinical trials for pulmonary LAM. Patients with LAM should be
encouraged to participate in clinical trials whenever possible.
2. In renal angiomyolipoma mTOR inhibitors should not be used as first-line therapy. Sirolimus may be considered on an
individual basis in patients with symptomatic angiomyolipoma or LAM related masses not amenable to embolisation or
conservative surgery in experienced centres.
3. In the current context of scientific uncertainty but possible treatment benefit, sirolimus may be considered on an
individual basis in patients with rapid decline in lung function or symptoms, after careful evaluation of risk/benefit
ratio in an experienced centre. When sirolimus is used, the effect of therapy should be carefully monitored for
tolerance and effect on lung function at 3 monthly intervals. Sirolimus should be stopped once patients are listed for
active lung transplantation.
Management of pneumothorax
1. Pneumothorax in LAM should ideally be managed jointly by a chest physician and thoracic surgeon.
2. A chemical pleurodesis may be performed at first pneumothorax. Patients who do not respond to initial therapy
including pleurodesis, should undergo an appropriate surgical procedure according to their clinical condition and local
expertise.
3. Patients with second pneumothorax should have an appropriate surgical procedure according to their clinical condition
and local expertise.
4. When transplantation is considered, patients with a history of pleurodesis or pleurectomy should be referred to
transplantation centres with experience of LAM to anticipate possible pleural complications.
5. A history of pleurodesis or pleurectomy should not be considered a contraindication to lung transplantation in patients
with LAM. However, patients should be informed of an increased risk of perioperative pleural bleeding
(continued on next page)
ERS LAM guideline methodology S39
Table 2 (continued)
Management of chylothorax
1. Patients with chylothorax may be placed on a fat free diet, with supplementation with mid-chain triglycerides.
2. For treatment of symptomatic chylous pleural effusions the decision to intervene and technique used should be
performed on an individual basis, based on clinical evaluation including amount of chyle collected, recurrence of
chylothorax, respiratory condition of the patient and consideration of future lung transplantation.
Treatment and follow up of angiomyolipoma
1. Patients should be advised to seek urgent medical attention in the presence of symptoms of bleeding angiomyolipoma.
2. Embolisation should be first-line treatment for bleeding angiomyolipoma. Nephron sparing surgery is also acceptable
dependent upon local expertise.
3. Embolisation should be performed as first-line therapy of angiomyolipoma in elective cases, with nephron sparing
surgery indicated where a malignant lesion cannot be excluded. Technical factors associated with the tumour blood
supply and local expertise should also be taken into account.
When is treatment of angiomyolipoma indicated in asymptomatic patients?
1. Asymptomatic renal angiomyolipoma under 4 cm should not be treated, but should be followed by yearly
ultrasound unless symptoms occur. Where ultrasound measurements are unreliable due to technical factors, CT or MRI
should be performed.
2. Renal angiomyolipomas greater than 4 cm or with renal aneurysms greater than 5 mm in diameter are at an
increased risk of bleeding, and should be followed by ultrasound imaging twice yearly to evaluate growth. Treatment
by embolisation or nephron sparing surgery should be considered.
Referral criteria for lung transplantation
1. Patients should be considered for lung transplantation when they reach NYHA functional class III or IV with hypoxemia
at rest, severe impairment in lung function and exercise capacity (VO2 max<50% predicted).
Which type of transplantation is indicated in LAM?
1. The choice of single, or bilateral lung transplant in LAM should be determined by surgical technical factors and organ
availability.
Special considerations related to lung transplantation for patients with TSC
1. Patients with TSC in the context of LAM should not be precluded from lung transplantation by TSC alone. Some patients
may have TSC related medical or cognitive problems which preclude transplantation.
2. TSCeLAM patients should have careful multi-disciplinary assessment when being evaluated for lung transplantation.
Does the presence of an angiomyolipoma affect lung transplant suitability?
1. Angiomyolipoma may not be a contraindication to lung transplantation but may affect transplant suitability, surgery
and postoperative follow up.
2. The presence of renal angiomyolipoma should be sought in the preoperative assessment, and those at risk of bleeding
should be treated prior to transplantation.
Should the possibility of recurrent LAM in the graft be investigated post transplant?
1. Routine investigation for recurrent LAM post transplantation with biopsy should not be performed.
Post transplant immunosuppression regimen for LAM
1. Post transplant regimen for patients with LAM should be the same as for other indications.
For the full document, including evidence levels please refer to the full manuscript19
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inhibitors should not be used as first-line therapy, Sirolimus
may be considered on an individual basis in patients with
symptomatic angiomyolipoma or LAM related masses not
amenable to embolisation or conservative surgery in
experienced centres e grade ‘C’, quality ‘L’, benefit ‘W’,
consensus ‘very good’. The last recommendation on mTOR
inhibitors concerns the difficult situation where patients
are deteriorating rapidly and developing respiratory failure
due to LAM. Many of these patients will either request
treatment with an mTOR inhibitor or have a drug recom-
mended by a physician. The Task Force stated that in the
current context of scientific uncertainty but possible
treatment benefit Sirolimus may be considered on an indi-
vidual basis in patients with rapid decline in lung function
or symptoms after careful evaluation of risk benefit ratio in
an experienced centre. When Sirolimus is used the effect of
therapy should be carefully monitored for tolerance andthe effect on lung function at three monthly intervals.
Sirolimus should be stopped on patients listed for active
lung transplantation e grade ‘C’, quality ‘L’, benefit ‘W’,
consensus ‘very good’. This recommendation again was
subjected to several iterations throughout the Delphi
process. The Task Force hopes that the guidelines for
example on mTOR inhibitors will allow clinical trials to
continue to take place and patients won’t be given
unproven therapies or put at undue risk if this is their only
therapeutic option. Recommendation 3 should ensure that
patients are at least discussed with a LAM specialist and
these drugs used in centres where expertise is appropriate.
In summary we have produced guidelines based upon
what evidence is available and expert practice. The
methods were adopted to take a consensus approach to
guide physicians through areas where their exposure to
these clinical problems is low and the level of evidence is
poor. The aim of the document was to standardise the
ERS LAM guideline methodology S41investigation and diagnosis of the disease guide manage-
ment and facilitate research in clinical trials. We are hoping
that the guidelines strategy should be prospectively eval-
uated to ensure that recommendations for example on the
diagnostic strategy are appropriate. It is hoped in the
future that the European Respiratory Society will join with
the American Thoracic Society and other groups to produce
a joint statement.
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